This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol. 2020;189:1171–81.
Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, et al. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv. 2020;4:3169–79.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645–53.
Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol. 2013;161:279–80.
de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99:1953–9.
Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, et al. Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis. Front Immunol. 2020;11:564647.
Cho BS, Yahng SA, Lee SE, Eom KS, Kim YJ, Kim HJ, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90:918–26.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transpl. 2016;22:1337–40.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22:307–15.
Jarmoliński T, Rosa M, Puziewicz-Zmonarska A, Kałwak K. Short course of eculizumab may be effective in dialysis-dependent transplantation-associated thrombotic microangiopathy after hematopoietic stem cell transplantation: a case report. Transpl Proc. 2020;52:2544–7.
Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2005;11:571–5.
Au WY, Ma ES, Lee TL, Ha SY, Fung AT, Lie AKW, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol. 2007;137:475–8.
Author information
Authors and Affiliations
Contributions
Conceptualization and Writing – Original draft preparation: MP, FSDF, and PC; Data curation: MP, FSDF, AB, LB, MC, MD, AM, EK, C-EB, AS, P-SR, VC, SC, SN-Q, RPL, and PC; Formal analysis: MP; Methodology and Supervision: FSDF and PC; Writing – Review & editing: MP, FS, AB, LB, MC, MD, AM, EK, C-EB, AS, P-SR, VC, SC, SN-Q, RPL, and PC.
Corresponding authors
Ethics declarations
Competing interests
PC received research grants and is a member of advisory board of Sanofi, Alexion, Takeda, Janssen. FSDF and RPL received honoraria and research support (to Saint-Louis Hospital, Paris) from Alexion, AstraZeneca Rare Disease, Samsung and Sobi.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Peyre, M., Sicre de Fontbrune, F., Berceanu, A. et al. Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02279-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02279-2